I did my PhD at the CBM in Madrid on the role of the carboxy-terminal region of tubulin on polymerization and MAP binding. Then I moved to the UK to work on protein folding. In 1993 I moved to the EMBL as a GL and started a new activity related to Protein design. After 6 years I was promoted to Senior Scientist. 2 years later I was appointed head of the Structural & Computational Biology programme. At that time we moved into the field of protein misfolding and amyloidoses diseases. We also started a new area of research on Systems Biology, designing small gene networks, doing computer simulations on them and performing experiments to test the predictions. After 14 years at the EMBL I moved to Spain to lead a programme working on Systems Biology. I was appointed vice-director before finally becoming the CRG director in July 2011. My group is focused on Synthetic Biology, engineering and designing of biological systems using our knowledge on protein design and gene networks.
The group of Luis Serrano is interested in the quantitative understanding and in the rational design of Biological Systems. To achieve this goal they combine theoretical and experimental approaches and develop appropriate software. Of particular interest for the group is the combination of protein design and network analysis to understand signal transduction and gene regulation. As a more ambitious project our group is now using Synthetic biology to engineer Mycoplasma pneumoniae as a living pill for human lung therapy. We also continue developing the software for protein design ModelX and FoldX, to engineer proteins with immunomodulatory activity. Finally we are exploting the role of codon usage and codon conservation in oncogenic proteins.
- Radusky LG & Serrano L 2022, 'pyFoldX: enabling biomolecular analysis and engineering along structural ensembles', Bioinformatics, 38(8):2353-2355.
- Piñero-Lambea C, Garcia-Ramallo E, Miravet-Verde S, Burgos R, Scarpa M, Serrano L & Lluch-Senar M 2022, 'SURE editing: combining oligo-recombineering and programmable insertion/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome', Nucleic Acids Research, 50(22):e127.
- Zadra I, Jimenez-Delgado S, Anglada-Girotto M, Segura-Morales C, Compton ZJ, Janke C, Serrano L, Ruprecht V & Vernos I 2022, 'Chromosome segregation fidelity requires microtubule polyglutamylation by the cancer downregulated enzyme TTLL11', Nature Communications, 13, 1, 7147.
- Anglada-Girotto M, Miravet-Verde S, Serrano L & Head SA 2022, 'robustica : customizable robust independent component analysis', Bmc Bioinformatics, 23, 1, 519.
- Ciampi L, Mantica F, López-Blanch L, et al. 2022, 'Specialization of the photoreceptor transcriptome by Srrm3-dependent microexons is required for outer segment maintenance and vision', Proc Natl Acad Sci USA, 119(29), e2117090119.
Selected research activities
Founder of Orikine Bio. Orikine Bio is based on the unique Foldikine technology developed at the lab of Dr. Luis Serrano. Its versatile platform delivers optimized best-in-class cytokines to maximize clinical benefits. Initial focus is on anti-inflammatory and regenerative auto-inflammatory and auto-immune diseases with potential to extend to other cytokines and diseases such as cancer and allergy.
Luis Serrano has been appointed Doctor honoris causa by the Miguel Hernandez University of Elche.